Effect of Alfacalcidol on Bone and Calcium Metabolism in Elderly Women.

DOI Web Site PubMed 25 References
  • Saito Shinichi
    Department of Internal Medicine; Metabolism, Endocrinology & Molecular Medicine, Osaka City University
  • Nakatsuka Kiyoshi
    Department of Internal Medicine; Metabolism, Endocrinology & Molecular Medicine, Osaka City University
  • Miki Takami
    Geriatric Medicine, Osaka City University
  • Naka Hiroshi
    Geriatric Medicine, Osaka City University
  • Kitatani Kayoko
    Department of Internal Medicine; Metabolism, Endocrinology & Molecular Medicine, Osaka City University
  • Nishizawa Yoshiki
    Department of Internal Medicine; Metabolism, Endocrinology & Molecular Medicine, Osaka City University
  • Morii Hirotoshi
    Aino Gakuin College

Bibliographic Information

Other Title
  • 高齢女性におけるアルファカルシドール投与の骨・カルシウム代謝に及ぼす影響
  • コウレイ ジョセイ ニ オケル アルファカルシドール トウヨ ノ ホネ カルシウム タイシャ ニ オヨボス エイキョウ

Search this article

Abstract

Oral administration of active vitamin D3 can reduce the loss of bone mass and the incidence of fractures in patients with osteoporosis in Japan. We conducted a prospective study to confirm the effects of 1α(OH)D3 (Alfacalcidol, Alfarol Chugai Tokyo) on bone and calcium metabolism in elderly women with osteoporosis. Enrolled in the present study were 16 elderly osteoporosis women aged 72.6±4.5 years to whom 1μg of 1α(OH)D3 was administered daily. Fasting blood and urine were obtained at baseline, 1 week, 4 weeks, 12 weeks and 24 weeks after the treatment. Monitored parameters were vitamin D metabolites, intact-PTH, bone alkaline phosphatase (BAP), osteocalcin (OC), deoxypyridinoline (DPD) and pyridiuium crosslinked type I collagen telopeptides (CTx). Serum 1α, 25(OH)2D and PTH levels were significantly increased (p<0.01) and decreased (p<0.05), respectively at 1 week after commencing administration. There was a significant decrease of DPD (p<0.05) at 12 weeks after commencing administration compared to the baseline levels.<br>Serum levels of BAP and OC were found elevated at 1 week, and decreased at 12 weeks. In conclusion, the present study clinically confirmed that 1α(OH)D3 stimulates bone formation in vitro. Long-term administration of 1α(OH)D3 indirectly suppressed bone resorption through the suppression of parathyroid function in the elderly.

Journal

References(25)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top